EE03973B1 - Faktori Xa inhibiitorid - Google Patents

Faktori Xa inhibiitorid

Info

Publication number
EE03973B1
EE03973B1 EE9600146A EE9600146A EE03973B1 EE 03973 B1 EE03973 B1 EE 03973B1 EE 9600146 A EE9600146 A EE 9600146A EE 9600146 A EE9600146 A EE 9600146A EE 03973 B1 EE03973 B1 EE 03973B1
Authority
EE
Estonia
Prior art keywords
activity
factor
compound
amino acids
provides
Prior art date
Application number
EE9600146A
Other languages
English (en)
Estonian (et)
Other versions
EE9600146A (et
Inventor
Al-Obeidi Fahad
Lebl Michal
A. Ostrem James
Safar Pavel
Stierandova Alena
Strop Peter
Walser Armin
Original Assignee
Selectide Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selectide Corporation filed Critical Selectide Corporation
Publication of EE9600146A publication Critical patent/EE9600146A/xx
Publication of EE03973B1 publication Critical patent/EE03973B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EE9600146A 1994-04-26 1995-04-25 Faktori Xa inhibiitorid EE03973B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23305494A 1994-04-26 1994-04-26
PCT/US1995/005268 WO1995029189A1 (en) 1994-04-26 1995-04-25 FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
EE9600146A EE9600146A (et) 1997-04-15
EE03973B1 true EE03973B1 (et) 2003-02-17

Family

ID=22875692

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600146A EE03973B1 (et) 1994-04-26 1995-04-25 Faktori Xa inhibiitorid

Country Status (27)

Country Link
EP (2) EP1384725A3 (sv)
JP (1) JP3655632B2 (sv)
KR (1) KR100380124B1 (sv)
CN (1) CN1181091C (sv)
AT (1) ATE262536T1 (sv)
AU (1) AU707653B2 (sv)
CA (1) CA2186497C (sv)
CZ (1) CZ296439B6 (sv)
DE (1) DE69532754T2 (sv)
DK (1) DK0758341T3 (sv)
EE (1) EE03973B1 (sv)
ES (1) ES2214500T3 (sv)
FI (1) FI120494B (sv)
HU (1) HUT76346A (sv)
IL (1) IL113505A (sv)
LT (1) LT4218B (sv)
LV (1) LV11740B (sv)
NO (1) NO318759B1 (sv)
NZ (1) NZ284977A (sv)
PL (1) PL188132B1 (sv)
PT (1) PT758341E (sv)
RU (1) RU2152954C1 (sv)
SI (1) SI9520044B (sv)
SK (1) SK286094B6 (sv)
TW (1) TW409129B (sv)
WO (1) WO1995029189A1 (sv)
ZA (1) ZA953361B (sv)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
UA48993C2 (uk) * 1995-12-20 2002-09-16 Авентіс Фармасьютікалз, Інк СПОСІБ ОТРИМАННЯ N-АЦЕТИЛ-(L)-4-ЦІАНОФЕНІЛАЛАНІНУ Аc-(L)-Phe(4-CN)-OH І N-АЦЕТИЛ-(L)-П-АМІДИНФЕНІЛАЛАНІН-ЦИКЛОГЕКСИЛГЛІЦИН-<font face="Symbol">b</font>-(3-N-МЕТИЛПІРИДИН)-АЛАНІНУ Аc-(L)-pАph-Сhg-PalMe(3)-NH<sub>2</sub>
US5766932A (en) * 1995-12-20 1998-06-16 Hoechst Marion Roussel, Inc. Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
WO1998046626A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046627A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046628A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
BR9814340B1 (pt) 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
BR9916732A (pt) * 1999-01-02 2001-09-25 Aventis Pharma Gmbh Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
EP1022268A1 (en) * 1999-01-02 2000-07-26 Aventis Pharma Deutschland GmbH Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1016663A1 (en) * 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
DE69924527T2 (de) * 1999-01-02 2006-02-09 Sanofi-Aventis Deutschland Gmbh Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
WO2001044171A1 (fr) * 1999-12-14 2001-06-21 Showa Denko K. K. Procede de production d'un sel de cyanobenzylamine ou de l'un de ses derives
JP5088598B2 (ja) * 1999-12-14 2012-12-05 昭和電工株式会社 シアノベンジルアミン類の塩の製造方法
WO2001055175A2 (en) * 2000-01-28 2001-08-02 Aventis Pharma Deutschland Gmbh Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
DE10029015A1 (de) 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
RU2003120070A (ru) 2000-12-06 2004-12-27 Авентис Фармаа Дойчланд Гмбх (De) Производные гуанидина и амидина в качестве ингибиторов фактора ха
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2003219039A1 (en) 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7446210B2 (en) 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
EP1724269A1 (en) 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
DE102005044319A1 (de) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP1918718A1 (de) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
CN103071154A (zh) 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275153A (en) * 1978-08-03 1981-06-23 American Hospital Supply Corporation Analytical fluorogenic substrates for proteolytic enzymes
CA1161431A (en) * 1979-05-11 1984-01-31 Lars G. Svendsen Tripeptide derivatives
US4469679A (en) * 1983-02-16 1984-09-04 Smithkline Beckman Corporation Octapeptide vasopressin antagonists
HU191961B (en) * 1984-08-02 1987-04-28 Richter Gedeon Vegyeszet Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
CA2129339C (en) * 1992-02-14 2002-09-10 George P. Vlasuk Inhibitors of thrombosis

Also Published As

Publication number Publication date
AU2368395A (en) 1995-11-16
NZ284977A (en) 1998-09-24
SK286094B6 (sk) 2008-03-05
EP1384725A2 (en) 2004-01-28
EP1384725A3 (en) 2007-02-21
CA2186497C (en) 2008-06-17
JPH10503477A (ja) 1998-03-31
SI9520044B (sl) 2004-08-31
SI9520044A (en) 1997-10-31
CN1147261A (zh) 1997-04-09
CZ314096A3 (en) 1997-05-14
EP0758341A1 (en) 1997-02-19
ZA953361B (en) 1996-01-12
NO964553D0 (no) 1996-10-25
LT4218B (en) 1997-09-25
ES2214500T3 (es) 2004-09-16
DE69532754T2 (de) 2005-03-10
CZ296439B6 (cs) 2006-03-15
PL317067A1 (en) 1997-03-03
FI964317A (sv) 1996-10-25
FI964317A0 (sv) 1996-10-25
LV11740B (en) 1997-12-20
PT758341E (pt) 2004-08-31
LT96151A (en) 1997-05-26
FI120494B (sv) 2009-11-13
RU2152954C1 (ru) 2000-07-20
ATE262536T1 (de) 2004-04-15
NO318759B1 (no) 2005-05-02
TW409129B (en) 2000-10-21
KR100380124B1 (ko) 2003-08-02
LV11740A (lv) 1997-04-20
CA2186497A1 (en) 1995-11-02
AU707653B2 (en) 1999-07-15
CN1181091C (zh) 2004-12-22
HU9602954D0 (en) 1996-12-30
SK136696A3 (en) 1997-05-07
EP0758341B1 (en) 2004-03-24
DE69532754D1 (de) 2004-04-29
IL113505A (en) 1999-12-31
PL188132B1 (pl) 2004-12-31
NO964553L (no) 1996-12-27
DK0758341T3 (da) 2004-06-28
IL113505A0 (en) 1995-07-31
WO1995029189A1 (en) 1995-11-02
JP3655632B2 (ja) 2005-06-02
HUT76346A (en) 1997-08-28
EE9600146A (et) 1997-04-15

Similar Documents

Publication Publication Date Title
LV11740A (lv) Xa faktora inhibitori
ATE102629T1 (de) Peptidderivate des blutplaettchen-aggregationsinhibitors.
DE69729583D1 (de) N-(amidinophenyl)-n&#39;-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
NZ500620A (en) Synthetic peptides which inhibit serine proteases, specifically thrombin, factor VIIa tissue factor and factor Xa
CO5261542A1 (es) Nuevos derivados tripeptidos como inhibidores de la hepatitis c, comprendiendo sus racematos, diasteroisomeros y procedimiento de preparacion
SE9602263D0 (sv) New amino acid derivatives
FI942625A0 (sv) Peptida fosfinyloximetylketoner som inhibitorer för interleukin-1beta-konverterande enzym
ATE181925T1 (de) Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
ATE153670T1 (de) Peptidboronsäurederivate mit protease inhibierenden aktivität
DE59900730D1 (de) Korrosionsinhibitoren enthaltender Injektionszement
MX9605037A (es) Inhibidores de factor xa.
DE59812724D1 (de) Serin-proteinase-inhibitoren
DE69615185D1 (de) Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
DE68908958T2 (de) Peptide.
ATE362545T1 (de) Screening-verfahren für substanzen zur behandlung von diabetes
RU94037136A (ru) Имидазолсодержащие ингибиторы катепсин-g-индуцированной агрегации тромбоцитов
NO950255D0 (no) Anvendelse av alfa,omega-dikarboksylsyrer som fibrinogenreduserende midler
TH38361A (th) สารยับยั้งเซรีนโปรทีเอส
HUP9601528A2 (hu) Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
TH20752EX (th) อนุพันธ์เพพไทด์ชนิดใหม่

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110425